Sorry, you need to enable JavaScript to visit this website.

Skip to main content

Search

Our Neuroscience Leadership Team

Leaders in Neuroscience

 

“Janssen Research & Development is committed to discovering and bringing to market innovative therapeutic solutions for people with brain disorders and pain."

Husseini Manji, M.D., F.R.C.P.C.

Global Head, Neuroscience

Neuroscience

Neuroscience

Nerve fibers
Nerve fibers

The Neuroscience Therapeutic Area is headed by Husseini Manji, M.D., F.R.C.P.C. Husseini was previously Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, National Institutes of Health (NIH), and director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a visiting professor at Duke University in Durham, North Carolina. He received his B.S. (Biochemistry) and M.D. from the University of British Columbia in Vancouver, Canada. Following residency training, he completed fellowship training at the National Institute of Mental Health (NIMH) and obtained extensive additional training in cellular and molecular biology at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The major focus of Husseini’s research has been the investigation of disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. His work has helped to conceptualize these illnesses as genetically influenced disorders of synaptic and neural plasticity, and has led to the investigation of novel therapeutics for refractory patients. He has also been actively involved in the development of biomarkers to help refine these multifactoral diseases into mechanism-based subcategories to develop targeted therapeutics.

Husseini is the recipient of numerous research and clinical awards, including the NIMH Director’s Career Award for Significant Scientific Achievement, the A.E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the National Alliance for Research on Schizophrenia and Depression (NARS AD) Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the Joel Elkes Award for distinguished research from the American College of Neuropsychopharmacology (ACNP), the Canadian Association of Professors Award, the Brown University School of Medicine Distinguished Researcher Award, the Depression and Bipolar Support Alliance (DBSA) Klerman Senior Distinguished Researcher Award, the American Federation for Aging Research Award of Distinction and the NIMH award for excellence in clinical care and research.

In addition to his neuroscience research and biomarker and therapeutics development endeavors, Husseini has also been actively involved in medical and neuroscience education undertakings, and has served as a member of the National Board of Medical Examiners (NMBE) Behavioral Science Test Committee, the Howard Hughes Medical Institute Research Scholars Program Selection and Advisory Committee and numerous national curriculum committees.

Husseini founded and co-directed the NIH Foundation for the Advanced Education in the Sciences Graduate Course in the Neurobiology of Neuropsychiatric Illness and received both the NIMH Mentor of the year and NIMH Supervisor of the year awards and the Henry and Page Laughlin Distinguished Teacher Award.

Husseini has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and the development of novel therapeutics. He was editor of Neuropsychopharmacology Reviews: The Next Generation of Progress, deputy editor of Biological Psychiatry, associate editor of the journal Bipolar Disorders and has been a member of the editorial board of numerous journals. He was inducted into the National Academy of Sciences’ Institute of Medicine (IOM), has been a Councilor of both the ACNP and Society of Biological Psychiatry, co-chairs the NIH Biomarkers Neuroscience Steering Committee, chaired the ACNP’s Task Force on New Medication Development, is a scientific advisor to the One Mind campaign (a public-private partnership that seeks to develop the United States’ first 10-year plan for research in neuroscience), has been named to the board of the International Neuroethics Society and is recent past president of the Society of Biological Psychiatry.

Husseini K. Manji, M.D., F.R.C.P.C.

Global Therapeutic Area Head, Neuroscience

Carine Brouillon is Global Commercial Strategy Leader for the Neuroscience Therapeutic Area. In this role, she directs the strategies and plans for Janssen Neuroscience pipeline products throughout the world. In partnership with Research & Development, Carine and her team are accountable for setting and executing the Neuroscience strategy, building disease area strongholds, maintaining the company's commercial strongholds, and developing deep areas of expertise in all commercial aspects. Her key areas of focus include market positioning of differentiated products and solutions, and development of global access strategies.

In addition, Carine is chairperson of the Janssen Sustainability Council. She leads the Council in its work to build awareness and engagement among employees, integrate sustainability into Janssen's business practices, and advance the company's reputation for leadership in citizenship and sustainability.

Carine joined Johnson & Johnson in 1997 as a product manager, and has held various positions of increasing responsibility in sales, marketing and general management. Previously, she served as President, Janssen Therapeutics. In this role, she was responsible for the United States commercial infectious diseases business, including driving growth for the company's HIV and hepatitis C medicines. She also served as a member of the Janssen North America Leadership Team.

Prior to joining Janssen Therapeutics, Carine was Managing Director, Austria and Switzerland, responsible for our pharmaceutical business in both countries. In that position, Carine led the integration of the Janssen companies in Switzerland and Austria into a single organization. Employee engagement remained high during this time of change, earning "Best Place to Work" accolades from a prestigious external organization in 2010, 2011 and 2012.

Carine also was Vice President, Sales and Marketing for Janssen France, responsible for the psychiatry, virology, nephrology and dermatology franchises. Under her leadership, Janssen France achieved significant market share gains for key products. Prior to this, Carine was European Business Director, Nephrology.

Prior to joining the company, Carine worked for five years at BioMérieux, a diagnostics company in France. She received her Doctor of Pharmacy Degree and Master's degree in Marketing and Management from the University of Lyon in Lyon, France.

Carine Brouillon

Global Commercial Strategy Leader, Neuroscience

Declan Jones, Ph.D. joined the Neuroscience team as Vice President of Neuroscience Scientific Innovation at Johnson & Johnson Innovation, London  in June 2013. Declan previously worked for GlaxoSmithKline’s (GSK) Centre of Excellence for External Drug Discovery (CEEDD) where, as Head of Research, he was responsible for creating scientific strategies, identifying new opportunities  and managing programs from preclinical to Phase II state programs across all therapeutic areas.

Prior to GSK’s CEEDD, Declan spent nearly 14 years in neuroscience drug discovery and development within GSK, finishing as Head of In Vivo Neurobiology and Disease Area Strategy Leader for schizophrenia and bipolar disorders within the Psychiatry Centre of Excellence for Drug Discovery and a member of the Biology Leadership team. His department was responsible for supporting the identification of 12 development candidate (NME) assets and provided in vivo support for a number of marketed assets. Declan was the recipient of a Research & Development Pipeline award in 2009 for his leadership of a schizophrenia program with a successful Phase II outcome.

Declan has over 75 peer-reviewed publications and external presentations and served as core panel member for Neuroscience on the Biotechnology and Biological Sciences Research Council (BBSRC) grant committee for a three-year term. He received his Ph.D. from the University of Bradford, United Kingdom and did post-doctoral work at Emory University in Atlanta, Georgia and University of Hertfordshire, United Kingdom, before joining the pharmaceutical industry. He chairs the Mood DAS Novel Targets Evaluation Forum (NTEF), and is currently an Executive Team member for the Dementias Platform UK and the Wellcome Trust Neuroinflammation Consortium and has recently joined the SAB for the South London and Maudsely NHS Foundation Trust Biomedical Research Centre at the Institute of Psychiatry, Psychology, and Neuroscience (King’s College London).

Declan N.C. Jones, Ph.D.

Vice President, Neuroscience Lead, Johnson & Johnson Innovation, London

Thomas Luby, Ph.D. is a Senior Director of New Ventures at Johnson & Johnson Innovation, Boston, focusing on early investments and collaborations in Neuroscience, Cardiovascular & Metabolism and Infectious Disease. Prior to joining the Johnson & Johnson Family of Companies, Tom worked at Shire, where he was the Senior Director of Research Ventures. In this position, he was involved in a number of successful early-stage investments in the rare disease space.

Tom has also held a variety of operational research and development roles in both start-up and mid-sized biotech. He has worked on multiple Discovery through Phase II programs in infectious disease, immuno-oncology and monogenetic disorders. His roles in both smaller and larger companies have allowed him to appreciate the opportunities and challenges of corporate partnerships in early-stage life sciences R&D. He firmly believes that larger company participation is essential to the success of the overall early-stage ecosystem, and remains committed to identifying teams and programs that can benefit from productive collaborations.

Tom received his Bachelor of Science degree in Biology from State University of New York, his Ph.D. in Immunology from Tufts University in Medford, Massachusetts and was a post-doctoral fellow in the Cancer Cell Biology Department at Harvard School of Public Health in Cambridge, Massachusetts.

Thomas M. Luby, Ph.D.

Senior Director, New Ventures, Johnson & Johnson Innovation, Boston

Eric Schaeffer, Ph.D. received his degree from the Albert Einstein College of Medicine in New York City, and went on to do post-doctoral fellowships at the Massachusetts Institute of Technology (MIT) and Rockefeller University in New York.  In 1994, Eric joined the Molecular Sciences department at Pfizer in Groton, Connecticut, where he held several positions within the Molecular Sciences and Neuroscience Discovery departments, ultimately as a Senior Director of Neuroscience Research, leading in vitro and in vivo pharmacology groups.  While at Pfizer, Eric was involved in advancing several compounds into early development for the treatment of depression, anxiety and bipolar disorder, and played a key role on the team that discovered the first FDA-approved non-nicotine replacement therapy for smoking cessation.

In 2009, Eric joined the Cure Huntington's Disease Initiative (CHDI) Foundation as Director of Neuropharmacology, where he led drug discovery teams in the identification of novel treatments for Huntington’s disease. In 2010, Eric accepted a position at Bristol Meyers Squibb as Director of Neuroscience Clinical Biomarkers, where he was responsible for the translational medicine strategy and tactics for the psychiatry portfolio. In 2014, Eric joined Janssen R&D as Senior Director in the Neuroscience External Innovations group. In his current role, Eric is responsible for managing a range of biotech and academic alliances focused on delivering novel therapies for the treatment of severe mood disorders and Alzheimer’s disease.

Eric Schaeffer, Ph.D.

Senior Director, Scientific Project Leader

Guy R. Seabrook, Ph.D. joined Janssen in 2012. His role as the Neuroscience Lead for the newly formed Johnson & Johnson Innovation, California is to help co-create and implement the external innovation plan to deliver the Neuroscience Therapeutic Area R&D Strategy. This includes solidifying Janssen’s place as an ideal partner in a highly competitive landscape of external collaborations. Our goals are to identify the best opportunities for value-generating collaborations and develop an industry-leading portfolio of investment opportunities. This involves the cultivation of a strong scientific network of experts in the global innovation community. He has more than 23 years of experience in drug discovery research, which includes preclinical research on marketed products and candidates in clinical development. Formerly, Guy was part of Eli Lilly’s Global External Research & Development (GER&D) organization where he led the GER&D team for the Lilly Bio-Medicines Business Unit, and also at Merck & Co, Inc., where he was the Head of the West Point Department of Alzheimer's Disease Research. He graduated with a Ph.D. in Zoology from the University of Nottingham, United Kingdom in 1987, and completed his postdoctoral research at the University of Miami School of Medicine, in Miami, Florida.

Guy R. Seabrook, Ph.D.

Vice President, Neuroscience Innovation, Johnson & Johnson Innovation, California

Luc is a highly regarded expert in early clinical and non-clinical development with a strong track record in developing and applying translational experimental medicine models and biomarkers.  He is a strong leader of people and teams, and has held management roles in clinical medicine and in global public health.

As leader of the Experimental Medicine group, Luc oversees design of clinical strategies and execution of clinical trials through Proof of Concept for all new molecular entities generated in the Janssen Neuroscience Therapeutic Area (TA). He has successfully integrated medical expertise into the drug discovery and early development process. Luc also serves as a member of the Janssen R&D Neuroscience Senior Leadership team.

He deployed the fast and lean process of clinical plan development, protocol development and trial execution, including lean trial visualization, and initiated several early development process improvement activities within and outside the Experimental Medicine group and across the five therapeutic areas. He served as Compound Development Team leader for several projects in early and late development.  Luc maintains close and fruitful collaboration with external partners, the Johnson & Johnson Innovation Centers, and academic institutions.

Luc is chairman of the Neuroscience TA Discovery/Development Review Committee (DDRC)   for Early Development. He also chairs the cross-TA Early Development Head Meeting, the Neuroscience Network Meeting in Beerse, and he is a member of the Johnson & Johnson First-In-Human Committee and the Janssen Campus R&D Senior Leadership Team in Beerse, Belgium.

Luc joined Janssen Research Foundation in Beerse in 1989 and advanced  through a variety of management positions, including Clinical Research Manager and Senior Clinical Research Manager, Cardiovascular Medicine; Associate Director, Internal Medicine; Director, Global Gastroenterology;  Senior Director, Global Experimental Therapeutics and Human Pharmacokinetics; Executive Director-Project Champion, Drug Evaluation; and Vice President, Experimental Medicine, Europe. He was named to his current role in 2009.

Before Luc joined Janssen, he practiced medicine and held management positions in clinical medicine and public health at St. Erasmus Hospital in Antwerp, Belgium, and The Ministry of Health, Zimbabwe, Africa.

Luc earned a medical degree from Catholic University, Louvain, Belgium, and completed postgraduate training in Tropical Medicine at Prince Leopold Institute, Antwerp. He also studied at the Vlerick School for Management, Leuven, Belgium. He is the author or coauthor of more than 75 publications and abstracts.

Luc Van Nueten

VICE PRESIDENT, EXPERIMENTAL MEDICINE, JANSSEN RESEARCH & DEVELOPMENT, LLC